Immutep
Immutep is a biotechnology company focused on developing LAG-3 related immunotherapy products for the treatment of cancer and autoimmune diseases. The company is pioneering the LAG-3 space and has clinical-stage assets targeting areas of high unmet need.
Short position
Immutep (ASX:IMM) has 1.07% of its shares on issue reported as short positions as of 5 Oct 2026, or about 15,826,532 shares. Over the past 30 days that figure has fallen 1.00 percentage points, and over 90 days it has fallen 1.38 percentage points. Its highest recorded short interest was 3.74% in July 2026. IMM is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Immutep (IMM) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $14.6MM (source: ASX (Markit))vs $60.1KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$79.3MM (source: ASX (Markit))vs −$61.4MM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- EPS (basic)
- n/avs n/a (FY25)
- Rev YoY
- n/mFY
- EPS YoY
- n/aFY
- ASX (Markit)
Summary of Appendix 4E & 2026 Full Year Statutory Accounts, 31 Aug 2026
Immutep reported revenue of A$14.6 million for FY2026, driven by a licensing deal with Dr Reddy’s, but its net loss widened 29.1% to A$79.3 million due to higher R&D costs and the discontinuation of its TACTI-004 Phase III trial. No dividend was declared. The company ended the year with A$68.9 million in cash, expects runway into H1 CY2028, and is conducting a root cause analysis to determine the path forward for its lead asset efti.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −543.3%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $14.6MM (source: ASX (Markit)) | $60.1KM (source: ASX (Markit)) | $119.6KM (source: ASX (Markit)) | $191.7KM (source: ASX (Markit)) |
| NPAT | −$79.3MM (source: ASX (Markit)) | −$61.4MM (source: ASX (Markit)) | −$42.7MM (source: ASX (Markit)) | −$39.9MM (source: ASX (Markit)) |
| Shares | 1.47B | n/a | 1.45B | 1.20B |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4E & 2026 Full Year Statutory AccountsAnnual Results31 Aug 2026via asx_announcements
- Immutep Quarterly Activities Report and Appendix 4CQuarterly Report30 Jul 2026via asx_announcements
- Immutep Quarterly Activities Report and Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results25 Feb 2026via asx_announcements
- Immutep Quarterly Activities Report and Appendix 4CQuarterly Report29 Jan 2026via asx_announcements
- Immutep Quarterly Activities Report and Appendix 4CQuarterly Report29 Oct 2025via asx_announcements
- Annual Report filed on Form 20-FAnnual Report27 Oct 2025via asx_announcements
- Annual Report to shareholdersAnnual Report24 Oct 2025via asx_announcements
- Appendix 4E & 2025 Full Year Statutory AccountsAnnual Results29 Aug 2025via asx_announcements
- Immutep Quarterly Activities Report and Appendix 4CQuarterly Report30 Jul 2025via asx_announcements
Showing 10 of 21 reports